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Introduction
Brachyuran whole crab ash is an ancient folk medication used to
treat solid tumors in the Middle East.1 Avicenna, a medical scientist,2 in
his 11th-century records precisely describes solid tumors and how whole
freshwater crab ash (CA) was used to treat the disease.3 Several recent
studies have demonstrated that the crab compounds derived from shell or
hemolymph have anticancer effects in vitro.1,4-6 For example, both
MCF7 breast carcinoma and LNCaP prostate carcinoma cells showed
reduced proliferation, increased apoptosis and decreased nitric oxide
(NO) production when treated with the ethanol extract of the shell of the
freshwater crab Potamon persicum.7,8 In addition, hemolymph of
brachyuran crab (Dromia dehaani) was reported to show cytotoxicity
against the hepatocellular carcinoma cell line, HepG2.9 Although the
active compound(s) leading to these anti-cancer effects is not known,
although it has been suggested that chito-oligosaccarides, chitosan,
carotenoids and selenium may play a role.1, 7
These data have led to increased interest in the anti-tumor activity of
novel crab extracts, including those derived from species of the genus
Portunus. Portunus is an abundant crab genus, comprising over 90
species, and is found in diverse regions. It contains several important
species for fisheries and is cultured in farms for human consumption.10
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There is very limited published data describing medicinal uses of
Portunus extract. A recent report describes the identification of a
glycosaminoglycan extracted from Portunus pelagicus as an inhibitor of
β-secretase 1 (BACE), which plays a role in the pathogenesis of
Alzheimer’s Disease.11 However, to our knowledge, there are no
publications describing anti-cancer properties of Portunus extract.
Data from the International Agency for Research on Cancer indicates
there were 17 million new cases of cancer worldwide in 2018, with this
projected to increase to 27.5 million new cases per year by 2040, if
recent trends continue.12 The most common cancers in 2018 were breast,
prostate, lung and colorectal.
Cutaneous melanoma was the 19th most common cancer worldwide in
2018 but shows significant variation in incidence rates across ethnic
groups, with fair skinned people the most affected.13 Melanoma is also
one of the most common cancers in young adults and as such, is
responsible for many years of life lost per death. Australia and New
Zealand have the highest incidence of melanoma with 15,229 new
diagnosed cases predicted in 2019.14
Until 2011, the main treatment of metastatic melanoma was dacarbazine,
which showed limited efficacy.15 Since then, the Food and Drug
administration (FDA) has approved immunotherapies, targeted therapies
and an oncolytic virus for treatment of melanoma.16 However, these
therapies can have significant side effects, and in the case of targeted
therapies (such as BRAF inhibitors), patients often acquire resistance
within months, limiting their clinical use.16 Thus, the identification and
development of new therapeutic options for melanoma remains a
priority.
In this study, the melanoma cell line SK-MEL-28 cell line was treated
with Portunus extracts, derived from whole crab ash (CA), shell, and
muscle fibers, at different concentrations. CA ethanol extract had the
greatest effect on cell proliferation, with 50% cell death after 24 hours at
1250 µg/mL. SK-MEL-28 cells were then treated with a sub-lethal
concentration of CA ethanol extract (750 µg/mL, 24 hours) and cell
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lysates subjected to proteome analysis. Compared to control cells, cells
treated with CA ethanol extract showed significant upregulation of 54
proteins, many of which were involved in protein folding, metabolic
dysregulation and the cellular cytoskeleton.
Materials and Methods
Crab taxonomic classification
The crab was purchased fresh from a food market. According to the
classification keys and identification criteria in published resources,10,
17-25 the crab used in this study belongs to the family, Portunidae;
subfamily, Portuninae; genus, Portunus. Figure 1 shows some
morphological features of this genus. The following features were used
to identify the crab as a member of the Portunidae family: 1) transversal
hexagon shaped carapace, slightly convex dorsal surface, broad front
and dental margin with several teeth or spines; and 2) lateral and last
flattened legs adapted for swimming, the later have paddle-like dactyl.
Features of the subfamily Portuninae were: 1) eyestalks are not long, 2)
chelipeds are the longer limbs. Genus Portunus determinant criteria were:
1) carapace width is more than its length, 2) margin has nine teeth
(spines) with the last one enlarged, 3) propodus granular and ridged, and
basal antennal joint is wide, 4) outer maxillipeds contain
semi-cylindrical segments of palp.10,17-25 This genus can be distinguished
from the genus Callinectes by its triangular male abdomen, which is an
inverted T shapee in Callinectes and the presence of inner spine on the
chelipeds.
Crab extract preparation
Six extracts were prepared including ethanol and aqueous extracts of
whole crab ash (CA), shell extract and protein extract. Whole CA was
obtained by heating the entire crab at 150oC for 2 hours before grinding
the crab into a powder. Shell extract was prepared as for CA, except
using only the shell. Protein extract was prepared by freezing and
lyophilizing the muscle fibres (Freeze Dryer, SCANVAC®, Germany),
prior to grinding into a powder.
For the ethanol extraction, each of the three powders were extracted
according to method described by Rezakhani et al.,7 as follows: for each
1 g crab derived powder, 30 mL 70% ethanol was added and the mixture
left in the dark at room temperature (RT) for 48 hours before being
filtered with filter paper. The filtrate was allowed to dry for 48 hours
before being lyophilised at -48°C, 0.563 Mbar for 24 hours. Following
this, extracts were resuspended in cell culture media without fetal bovine
serum (described below) and filter sterilized through a 0.22 µm filter.
The aqueous extracts were prepared for CA, shell, and muscle fibres, as
for the ethanol extraction, except that distilled water was used as the
initial solvent instead of 70% ethanol.
Cell Culture
SK-MEL-28 media included 90% v/v Roswell Park Memorial Institute
(RPMI) 1640 Medium, 1 mM sodium pyruvate, 2 mM glutamine, and 10
mM HEPES buffer (all from Gibco®, Life Technologies, Carlsbad, CA)
and 10% fetal bovine serum (FBS) (Serana, Bunbury, Australia). Cells
were thawed, seeded into 25 mL flasks and incubated in a humidified
incubator at 37°C and 5% CO2. Cells were grown to 70 - 85%
confluence before passaging (every 2-3 days). After several passages,
cells were seeded into 24 well plates (5 × 104 cell/well) for treatment
with crab extract.
Crab extract treatment
Each of the extracts were added to the cell line in the concentrations of
5000, 2500, 1250, 625, 312.5, and 156.25 µg/mL in normal growth
media, in triplicates in a 24 well plate. The results were observed after
24, 48, and 72 hours and the concentrations then narrowed to 2500, 1250,
950, 625, 312.5 µg/mL. Combinations of shell and protein extracts
(50/50) were also prepared at total concentrations of 1200, 1000 and 800
µg/mL and cells observed over 72 hours. Control cells were grown in
culture media alone.
Cytopathic effect (CPE)
Cells were observed for rounding up26 and blebbing,27 which are
morphological changes associated with apoptosis, known as cytopathic
effect (CPE). These changes were observed via inverted light
microscopy (Olympus, Tokyo, Japan) at 400x magnification and
rounded cells counted manually in non-overlapping fields of view.
DAPI staining
4',6-Diamidino-2-Phenylindole (DAPI) staining was used to visualize
the nucleus of control and treated cells, to identify if nuclear damage
such as shrinkage or fragmentation, had occurred.26, 28 Control cells and
cells treated with 1250 and 950 µg/mL CA ethanol extract were washed
with phosphate buffered saline (PBS) (Sigma-Aldrich, St Louis, MI)
twice, and 0.3 µM DAPI (Thermo Fisher Scientific, Waltham, MA) in
PBS was added and incubated in the dark for 5 min. Cells were rinsed
with PBS twice before being fixed in 4% paraformaldehyde (PFA) in
PBS.
Preparation of cell lysate from SK-MEL-28 for mass spectrometry
SK-MEL-28 cells were grown in two 25 cm2 flasks, and when near
confluence, one flask treated with 750 µg/mL CA (treated), and the other
allowed to grow in normal medium (control) for 24 hours. The media
was removed, cells washed in PBS and detached by incubating with 2.5
mM Ethylenediaminetetraacetic acid (EDTA) at 37℃ for 2 min,
followed by mechanical disruption using a plastic cell scraper. Cells
were collected in 5 mL PBS and centrifuged at 1200 rpm for 5 min at
20℃. The cells were then washed in 5 mL PBS and re-centrifuged. The
cell pellet was resuspended in 200 µL lysis buffer (PBS, 1% NP40, 1x
cOmplete™ protease inhibitor; all from Sigma Aldrich), incubated on
ice for 30 min and centrifuged at 12000 rpm at 4℃ for 10 min. The
supernatant was harvested, and protein concentration measured before
being stored at -20℃.
BCA Protein Assays
The Bicinchoninic acid assay (BCA) kit (Thermo Fisher Scientific) was
used to estimate the protein concentration in SK-MEL-28 cell lysates.
Briefly, a standard curve was constructed by serial dilution of 1 mg/mL
bovine serum albumin in the wells of a 96-well plate, and a range of cell
lysate volumes were tested. Following the addition of the BCA reagent,
the assay was incubated at 37oC for 30 min before the absorbance
measured at 562 nm (EnSpire Multimode Plate Reader, PerkinElmer,
Waltham, MA). Standard curves and concentrations were calculated
using Microsoft Excel.
Acetone Precipitation
900 µL of -20°C cooled acetone was added to the treated and control
cell lysates, vortexed, incubated in -20°C for 1 hour, and then
centrifuged at 14 000 x g for 10 min. The supernatant was removed, and
the precipitated proteins were air dried at 20oC for 30 min.
Mass Spectrometry
The protein samples of treated and control cells were processed by
Proteomics International (PI) laboratories, NATA ltd (Nedlands,
Australia). Samples were reduced, alkylated and trypsin digested
according to the iTRAQ protocol (Sciex). Samples were analysed by
electrospray ionisation mass spectrometry using the Shimadzu
Prominence nano HPLC system (Shimadzu) coupled to a 5600
TripleTOF mass spectrometer (Sciex). Peptides were loaded onto a
Zorbax 300SB-C18, 3.5 μm separation column (Agilent Technologies)
and separated with a linear gradient of water/acetonitrile/0.1% formic
acid (v/v). ProteinPilot™ 5.0 (SCIEX) was applied against Swissport
database to identify the peptides.
The total number of distinct peptides identified was 2074 for treated and
1347 for control (>95% confidence level). This was reduced to 366 for
treated and 261 for control, when only proteins with two unique peptides
(>95% confidence level) were considered. When these two protein data
sets were compared. This smaller number of unique proteins underwent
analyses. The global and local False Discovery Rate (FDR) was <0.1%.
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Functional Annotation
In addition to text mining, Visualization and Integrated Discovery
(DAVID) v6.8 29, as well as Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) protein interactions tool version 10.5 30 were
used.
Statistical analysis
Fisher’s exact test applied to identify significant changes in unique
peptide quantity between control and treated cell lysates, with p<0.10
considered significant.
Results and Discussion
Treatment of SK-MEL-28 melanoma cells with ethanol and aqueous
crab extracts
SK-MEL-28 cells showed higher levels of CPE (e.g. cell rounding) and
cell death when treated with ethanol extracts compared to aqueous
extracts (Figures 2 - 4, Table 1). Aqueous extracts of whole crab ash
(CA), shell and muscle protein were associated with minimal cell death
or morphological changes at all concentrations up to 2500 µg/mL (CA)
or 5000 µg/mL (Figure 2, Table 1). This suggests that the aqueous
extraction method was a poor method of extracting potentially cytotoxic
compounds from the Portunus sp. crab. This is consistent with
Al-Shammari et al, who reported that burned crab shell extracted in
methanol was more effective at inhibiting cellular proliferation than an
aqueous extract.1
In contrast, SK-MEL-28 cells treated with ethanol extracts displayed
CPE and cell death at concentrations greater than 1250 µg/mL (Figures
3, 4; Table 1). In particular, ethanol whole crab ash (CA) extract was
associated with cell death at lower concentrations than ethanol shell or
protein only extracts. Ethanol CA extract at 2500 µg/mL was associated
with 100% cell death at 24 hours and clear morphological changes at
1250 µg/mL (48-58% cell rounding) (Figure 3, Table 1). In contrast,
ethanol shell and protein extracts showed minimal morphological
changes at 1250 µg /mL (6 – 10% rounding) and modest changes at
5000 µg/mL (20-24% rounding) (Figure 4, Table 1).
Interestingly, combining ethanol shell and protein extracts was
associated with increased cell death and rounding (22-28% at 1200
µg/mL) compared to when the ethanol shell and protein extract were
applied separately (5 – 8% at 1250 µg/mL) (Figure 3). This suggests
there may be a combination of molecules when these two were applied
together than stimulated increased CPE and cell death in the
SK-MEL-28 cells. However, extracting the shell and protein separately
and then combining them did not cause the same level of morphological
changes or cell death as when similar concentrations of whole crab ash,
extracted in a single process, were applied to the cells. For example, at
1200-1250 µg/mL there was 48 - 57% cell rounding in CA extract
compared to 22 - 28% in the combined shell/protein extract. This may be
because the ethanol extraction of bioactive molecules from whole crab
was more efficient than separate extractions. In addition, the CA extract
and protein extract were prepared differently. CA extract was subjected
to 150oC for 2 hours, which would have denatured all proteins in the
crab muscle, whereas the ethanol protein extract may have contained
active peptides. Al-Shammari also found burnt crab extract to be more
effective than non-heated crab shell extract and hypothesized that the
heating process may lead to the formation of novel complexes in the
crab shell not seen in the native (non-burned) state.1 It is possible that
the heating process of our whole crab extract, which would lead to
denatured protein, has produced a novel compound or conformation with
increased cytotoxicity, which is not contained in non-heated protein
material. As the ethanol CA extract was found to be the most effective,
further microscopic analyses was performed on SK-MEL-28 cells. Cells
treated with 1250 µg/mL ethanol CA extract showed signs of apoptosis
such as membrane blebbing and cell rounding up,26,27 as well as a
granulated cytoplasm; when compared to control cells (Figure 5).
Melanoma cells treated with a lower concentration of 625 µg/mL also
showed clear areas near the nucleus (Figure 5). Further studies using
DAPI staining also revealed the presence of pyknotic nuclei in cells
treated with ethanol CA extract, with increasing nuclear changes seen
with increasing concentration, as well as fewer cells per field of view
(Figure 6). These data are consistent with that of Rezakhani et al, who
found a similar concentration (1000 µg/mL) of Potamon Persicum
ethanol extract was associated with cell viability of approximately 75%
in LnCap prostate and MCF7 breast cancer cells at 24 hours exposure,
which fell to approximately 50% at 72 hours. In both cell lines, TUNEL
assays confirmed a dose-dependent relationship between the extract and
levels of apoptosis.7,8 Cell viability and signs of apoptosis (e.g.
membrane blebbing) also increased at 48 and 72 hours in our assays
(data not shown).
Mass Spectrometry (MS) and Functional Annotation
Approximately 40-50% of SK-MEL-28 cells survived treatment with
1250 µg/mL of ethanol CA extract over 24 hours, which suggests these
cells may be able to tolerate the cytotoxic compound(s) contained in the
extract. Understanding the mechanisms that enable cell survival may
provide information about the pathways stimulated by this extract and
the nature of the chemoresistance seen in these cells.
SK-MEL-28 cells were treated with a sublethal dose (750 µg/mL) of CA
ethanol extract, or medium only (control) for 24 hours. Protein lysates of
treated and control cells were analysed by mass spectrometry (MS),
followed by functional analysis applying bioinformatics online tools and
text mining. There were 54 proteins that were significantly upregulated,
based on the number of unique peptides identified, in treated cells
compared to untreated cells (Fishers exact test, p < 0.1) (Table 2).
However, it must be noted that this MS analyses was semi-quantitative.
As such, these data provide some clues about the cellular response to the
crab extract applied, which require validation and further investigation.
The proteins with altered levels in treated versus control cells were
grouped into categories based on their primary roles and/or locations
within the cell. As many proteins have multiple functions, the grouping,
discussion and interpretation is not exhaustive (Table 2).
Protein synthesis, folding, degradation; endoplasmic reticulum (ER)
chaperone proteins
The largest group of proteins that were upregulated in treated cells were
those involved in protein synthesis, folding and ER chaperones,
suggesting cellular stress was induced in the SK-MEL-28 cells by the
crab extract. Following cellular stress, cells have to cope with protein
damage in order to survive. To do this they have developed a dual
response – damaged proteins are either repaired or eliminated, via
molecular chaperones and proteolysis, respectively.31
A number of members of the cytoplasmic heat shock protein (HSP)
family were upregulated, including HSP90α, HSP90β, HSP70 members
2/8, and protein deglycase; in addition to the delta, epsilon and zeta
subunits of the chaperonin, T-complex protein (TCP) (CCT4, CCT5,
CCT6a). A number of other studies have found upregulation of
cytoplasmic molecular chaperones in chemo-resistant cancer cells,
suggesting HSP upregulation is involved in chemo-resistance. For
example, cisplatin-resistant cervical cancer cells32 and
paclitaxel-resistant ovarian cells33 both showed upregulation of HSPs
and other molecular chaperones/chaperonins, including the TCP subunits.
Misfolded proteins in the endoplasmic reticulum (ER) are processed via
ER resident chaperones, a number of which were also upregulated in
treated SK-MEL-28 melanoma cells. A role for ER chaperone proteins
in chemo-resistance has been previously described. For example,
prolyl-4-hydroxylase subunit β has been implicated in temozolomide
resistance in glioma34 and peptidyl-prolyl cis-trans isomerase A has been
implicated in paclitaxel resistant breast cancer cells.35
Several proteins involved in degradation (transitional ER ATPase, and
ubiquitin-like modifying activating enzyme) were also upregulated in
treated cells, along with molecules associated with the redox level of the
cell, e.g. peroxiredoxin-1 and glutathione S-transferase P. This is
consistent with Di Michele et al.33 who describe increased levels of
peroxiredoxin-2, 3 and 6 in cisplatin-treated ovarian cancer cells, and
Castagna et al.32 who described upregulation of peroxiredoxins-2 and 6
and glutathione-S-transferase in cisplatin treated cervical cancer cells.
There was also upregulation of a number of proteins involved in protein
synthesis/translation, namely elongation factors and the components of
the small and large ribosomal subunits. mRNA translation elongation
has been studied in melanoma, with eukaryotic translation initiation
factor 5A (eIF5a) associated with tumour thickness and poor prognosis36
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Figure 1: Portunus sp morphological features. A, maxilliped; B, antenna; C, front view; D, abdominal view;
E, legs; F, dorsal whole view; G and L, chelipeds; H, front board; and I, carapace.
and eukaryotic elongation factor 2 (eEF2) identified as a potential serum
biomarker in melanoma.37 Interestingly, elongation factor 1 delta
(EF1-delta) was described as one of four proteins upregulated in
melanoma cells treated with cisplatin, vindesine, fotemustine and
etoposide to produce drug resistant sub-lines,38 but there are no recent
publications describing the role of this protein in melanoma. It is
possible that elongation factors may contribute to chemoresistance in
melanoma and/or provide options for therapeutic targeting, but current
data is limited and this area requires further investigation. 39
Metabolic changes (glycolysis, lipid metabolism, mitochondrial
proteins)
A number of proteins involved in glycolysis were upregulated in treated
SK-MEL-28 cells including alpha enolase, pyruvate kinase,
glyceraldehyde-3-phosphate dehydrogenase, glucose-6-phosphate
isomerase, hexokinase-2 and L-lactate dehydrogenase A chain (Table 6).
In addition, a key regulator of the citric acid cycle, isocitrate
dehydrogenase, was upregulated, along with fatty acid synthase.
Interestingly, two components of the ATP synthase complex involved in
oxidative phosphorylation (OXPHOS) in the mitochondria showed
increased expression in treated cells, suggesting that both glycolysis and
OXPHOS are active in treated cells. Moreover, the increase in fatty acid
synthase may suggest that some of the pyruvate produced in glycolysis
is converted into fatty acids. Aerobic glycolysis, or the Warburg effect,
is a hallmark of cancer.40 The Warburg effect describes the increased use
of glycolysis rather than OXPHOS by tumor cells in physiological
oxygen conditions (reviewed in Bhattacharya et al).41 Although
OXPHOS produces larger amounts of ATP, it is slower to respond to
changing conditions, whereas glycolysis can respond quickly. It has
been proposed that tumor cells can optimize energy production by
maintaining a mix of glycolysis and OXPHOS, where glycolysis may be
used to meet short term increases in energy demands.42 Interestingly,
upregulation of alpha-enolase (ENO1), with associated increased
glycolysis, was described in cisplatin-resistant cells in gastric cancer,
and associated with poor patient outcomes.43 Moreover, ENO1
knockdown was found to reduce glycolysis, increase OXPHOS, and
cause growth arrest.44,45 Other studies have found increased aerobic
glycolysis is important in maintaining chemo-resistance, and it has been
hypothesised that glycolytically-derived ATP contributes to, among
other things, drug inactivation and increased intracellular survival
signalling.46 The upregulation of the mitochondrial MICOS complex
subunit MIC60 (IMMT) and mitochondrial 60kDa HSP suggests there
may have been some mitochondrial damage/stress associated with the
treatment – MIC60 is a core unit of MICOS, which regulates cristae
morphology and protein transport;47 while mitochondrial HSP60
maintains proteins in an unfolded state to enable transport across the
inner mitochondrial membrane.48
Nuclear proteins
Poly (ADP-ribose) polymerase 1 (PARP-1) and X-ray repair
cross-complementing protein 5 (XRCC5) are involved in single stranded
and double stranded DNA repair, respectively. Intuitively, increased
DNA repair mechanisms could be associated with chemo-resistance, and
indeed with PARP-1, this seems to be the case. Increased PARP activity
is believe to be associated with resistance to DNA damaging agents.49
However, for XRCC5 in melanoma, there have been conflicting reports -
in some studies increased levels of XRCC5 have been associated with
worse patient outcomes,50 whereas in others the reverse was true.51
There is no data regarding XRCC5 and chemo-resistance.
Nucleophosmin (NPM1) is known to be involved in a number of
pathways including mRNA transport, chromatin remodelling and
apoptosis, but has also recently been implicated in genome stability and
DNA repair (homologous recombination).52 In addition, recent data has
suggested reduced levels of NPM1 are associated with chemotherapeutic
sensitivity53 whereas elevated levels confer multiple drug resistance in
breast cancer cells.54 Heterogeneous nuclear ribonucleoprotein A1
(HNRNPA1) and polypyrimidine tract-binding protein 1 (PTBP1) are
both members of the heterogeneous nuclear ribonucleoprotein family
that bind to pre-mRNAs in the nucleus and affect pre-mRNA processing
and transport. PTBP1 has been implicated in melanoma via its role in
splicing CD44,55 a cell surface molecule involved in migration
metastasis. Conversely, in breast cancer PTBP1 activity is believed to
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Figure 2: SK-MEL-28 cells treated with aqueous extracts of A) whole crab ash, B) shell and C) protein, for
24 hours. All images were taken at 100x magnification on an inverted phase contrast microscope and captured
using the Olympus cellSens platform.
Figure 3: SK-MEL-28 cells treated with ethanolic whole crab ash (CA) extract for 24 hours. All images were
taken at 100x magnification on an inverted phase contrast microscope and captured using the Olympus cellSens
platform.
Control 5000 µg/mL 1250 µg/mL
Control 5000 µg/mL 1250 µg/mL
Control 2500 µg/mL 1250 µg/mL
B. Aqueous shell extract
C. Aqueous protein extract
A. Aqueous whole CA extract
950 µg/ml 625 µg/mL 312.5 µg/mL
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Figure 4: SK-MEL-28 cells treated with ethanolic extracts of A) shell, B) protein, and C) combined shell and
protein for 24 hours. All images were taken at 100x magnification on an inverted phase contrast microscope
and captured using the Olympus cellSens platform.
Table 1: Percentage of cell rounding in SK-MEL-28 cells treated with ethanolic and aqueous Portunus extracts for 24 hours.
Percentage of rounded up cells
Extract
Conc.
(µg/mL)
Ethanolic
CA
Ethanol
shell
Ethanol
protein
Ethanol
shell +
protein
Aqueous
CA
Aqueous
shell
Aqueous
protein
0 5% 5% 5% 5% 5% 5% 5%
312.5 6-8% 5-7% 5-7% 5-7% 5-7% 5-7%
625 14-18% 5-7% 5-7% 5-7% 5-7% 5-7%
950 27-32%
1250 48-57% 6-8% 5-7% 22-28%1 5-7% 6-8% 5-7%
2500 100% 6-10% 8-10% 18-24% 8-12% 5-7%
5000 20-24% 22-24% 22-25% 5-7%
11200 µg/mL (600 µg/mL shell + 600 µg/mL protein extract)
Control 1200 µg/mL 800 µg/mL
A. Ethanolic shell extract
Control 5000 µg/mL 1250 µg/mL
B. Ethanolic protein extract
C. Ethanolic shell and protein extract combined
Control 5000 µg/mL 1250 µg/mL
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Figure 5: Apoptosis-related cytopathic effect (CPE) in SK-MEL-28 cells treated with 1250 ug/mL ethanolic CA extract. A, blebbing
(400x, zoom); B, cell roundup (200x, zoom); C, Dark granules in the cytoplasm (200x, zoom); D, Clear area around the nuclei (this is a
625 ug/mL CA ethanolic extract treated cells)(200x); E, control (100x). Images were taken at on an inverted phase contrast microscope
and captured using the Olympus cellSens platform.
Figure 6: DAPI staining after 24 hours of treatment with ethanolic CA extract. Nuclear pyknosis is indicated. Top images are taken at
400x magnification, bottom images at 100 x magnification. Images were taken at on an inverted fluorescent microscope and captured
using the Olympus cellSens platform.
regulate splicing of pyruvate kinase and contribute to altered glucose
metabolism.56 Interestingly HNRNPA1 has also been shown to regulate
CD44 splicing in hepatocellular carcinoma, with expression associated
with poor prognosis.57 However, there is no data available regarding the
contribution of HNRNP family members to chemo-resistance.
Cytoskeletal proteins
The contractive proteins, myosin-9 and β-actin were upregulated in
treated cells, as was the actin binding protein α-actinin-4 and two tubulin
isoforms (α-1B chain and β-4B chain). Di Michele et al.33 also describe
changes in a range of cytoskeletal proteins in paclitaxel treated cells, but
in contrast to our study, found decreased β-actin. The actin cytoskeleton
provides a scaffold for the cell and is essential for cellular functions
including cell migration, endocytosis and vesicular trafficking,
cytokinesis and apoptosis.58 Actin interacts with actin binding proteins
(ABPs) such as cofilin and α-actinin and is regulated by Rho GTPases,
which control ABP function, leading to changes in actin structures such
as the formation of stress fibres and lamellipodia.58 Several reports have
reported that changes in actin cytoskeleton organisation in osteosarcoma
and leukaemic cells are associated with drug resistance and worse
prognosis (reviewed in Desouza et al.58). In addition, increased
actin/myosin expression may also represent a more motile/metastatic
phenotype of surviving cells. Tubulins are components of the
microtubule cytoskeleton. During interphase, microtubules are involved
in maintenance of cell shape and trafficking intracellular proteins and
organelles, whereas during mitosis microtubules form the mitotic spindle
integral to chromosome segregation.59 Some chemotherapeutics directly
target microtubules and suppress microtubule dynamics, leading to
failure of mitosis.60 Recently Wang et al.61 described a novel inhibitor of
CA
B
D E
Control 950 µg/mL 1250 µg/mL
Control 950 µg/mL 1250 µg/mL
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Table 2: Upregulated proteins in SK-MEL-28 melanoma cells after treatment with 750 µg/mL ethanolic CA for 24 hours.
Uniprot Accession #
Gene Name
# Peptides
C1 T2
Protein Synthesis
P07237 Elongation factor 1-alpha 1 (EEF1A1) 15 24
P13639 Elongation factor 2 (EEF2) 11 22
P05387 60S acidic ribosomal protein P2 (RPLP2) 0 8
P24534 Elongation factor 1-beta (EEF1B2) 0 5
P15880 40S ribosomal protein (RPS2) 0 4
P55884 Eukaryotic translation initiation factor 3 subunit B (EIF3B) 0 4
Protein folding, degradation and oxidative stress
P11142 Heat Shock Protein Family A (Hsp70) Member 8 (HSPA8) 16 22
P55072 Transitional endoplasmic reticulum ATPase (VCP) 13 21
P08238 Heat shock protein HSP 90-beta (HSP90AB1) 11 23
P07900 Heat shock protein HSP 90-alpha (HSP90AA1) 10 24
Q99497 Protein deglycase/Parkinson disease protein 7 (PARK7) 4 11
P22314 Ubiquitin-like modifier-activating enzyme 1 (UBA1) 2 11
P48643 T-complex protein 1 subunit epsilon (CCT5) 2 9
Q06830 Peroxiredoxin-1 (PRDX1) 2 8
P40227 T-complex protein 1 subunit zeta (CCT6A) 1 7
P54652 Heat shock-related 70 kDa protein 2 (HSPA2) 0 7
P09211 Glutathione S-transferase P (GSTP1) 0 6
P50991 T-complex protein 1 subunit delta (CCT4) 0 5
ER chaperones
P07237 Prolyl 4-hydroxylase subunit beta (P4HB) 9 17
P14625 Heat shock protein 90 kDa beta member 1 (HSP90B1) 6 13
P27824 Calnexin (CANX) 3 11
P23284 Peptidyl-prolyl cis-trans isomerase B (PPIB) 1 7
P13667 Protein disulfide-isomerase A4 (PDIA4) 0 7
Glycolysis and Metabolism
P06733 Alpha-enolase (ENO1) 21 44
P14618 Pyruvate kinase PKM (PKM) 19 34
P04406 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 13 38
P00338 L-lactate dehydrogenase A chain (LDHA) 6 22
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) 1 6
P06744 Glucose-6-phosphate isomerase (GPI) 1 6
P52789 Hexokinase-2 (HK2) 0 6
Lipid metabolism and lipid binding proteins
P49327 Fatty acid synthase (FASN) 9 20
P08758 Annexin A5 (ANXA5) 6 17
P04083 Annexin A1 (ANXA1) 5 12
Q00341 Vigilin (HDLBP) 0 6
Mitochondrial proteins
P10809 60 kDa heat shock protein, mitochondrial (HSPD1) 16 37
P06576 ATP synthase subunit beta, mitochondrial (ATP5B) 8 19
P25705 ATP synthase, mitochondrial alpha subunit 1, (ATP5F1A) 6 13
Q16891 MICOS complex subunit MIC60 (IMMT) 0 6
Nuclear proteins
P13010 X-ray repair cross-complementing protein 5 (XRCC5) 5 12
P09874 Poly [ADP-ribose] polymerase 1 (PARP1) 1 6
P09651 Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) 0 7
P26599 Polypyrimidine tract-binding protein 1 (PTBP1) 0 6
P06748 Nucleophosmin (NPM1) 0 6
Q96AG4 Leucine-rich repeat-containing protein 59 (LRRC59) 0 5
Cytoskeleton and cytoskeletal binding/regulating proteins
P35579 Myosin-9 (MYH9) 16 26
P60709 Actin, cytoplasmic 1 (ACTB) 15 26
P68363 Tubulin alpha-1B chain (TUBA1B) 13 29
O43707 Alpha-actinin-4 (ACTN4) 7 19
P68371 Tubulin beta-4B chain (TUBB4B) 0 20
Trop J Nat Prod Res, April 2019; 3(4):113-123 ISSN 2616-0684 (Print)
ISSN 2616-0692 (Electronic)
© 2019 the authors. This work is licensed under the Creative Commons Attribution 4.0 International License
121
Q14204 Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1) 0 9
Other proteins
Q09666 Neuroblast differentiation-associated protein (AHNAK) 18 40
P46940 Ras GTPase-activating-like protein IQGAP1 (IQGAP1) 5 15
P05023 Sodium/potassium transporting ATPase subunit alpha (ATP1A1) 2 7
P31949 Protein S100-A11 (S100A11) 0 4
tubule polymerisation that reduced lung metastasis in a murine
melanoma model, demonstrating tubulin is a potential target in
melanoma treatment. Thus, upregulation of tubulin may also be involved
in chemo-resistance.
Other proteins
Neuroblast differentiation-associated protein (AHNAK), Ras
GTPase-activating-like protein (IQGAP1), sodium/potassium
transporting ATPase subunit alpha (ATP1A1), and S100
calcium-binding protein (S100A11) did not fit well into any of the
previous categories and were listed separately. AHNAK is described as a
large scaffolding protein and is believed to contribute to actin
cytoskeletal organisation and cell-cell contacts. A recent study has
described reduced AHNAK expression in melanoma compared to
melanocytes,62 whereas we observed an increase in our treated cell line.
IQGAP1 belongs to a family of scaffold proteins that contribute to that
cytoskeletal dynamics, and intracellular signalling, and is often over
expressed in cancer.63 Recently, Pan et al.64 identified the O‐class
forkhead factor, FOXO1, as a binding partner of IQGAP1. These authors
describe that phosphorylated FOXO1 binds to IQGAP1 in the cytoplasm
to decrease IQGAP1-dependent activation of the ERK/MAPK pathway.
This interaction is blocked by taxane based chemotherapeutics, leading
to IQGAP1 activation of the extracellular signal-regulated kinase/
mitogen-activated protein kinase (ERK/MAPK) pathway and
chemo-resistance.64 Thus, IQGAP1 upregulation may be contributing to
resistance in our treated melanoma cells.
Conclusion
This study reveals that an ethanol extract of whole crab ash, from the
crab of the genus Portunus, resulted in reduced proliferation and
apoptosis in the SK-MEL-28 melanoma cell line. Ethanol extracts of
shell alone or protein alone, and aqueous extracts, were much less
cytotoxic compared to the ethanol whole crab ash extract. This suggests
that the cytotoxic agent/s were extracted more efficiently with ethanol.
In addition, the heating involved in preparation of the whole crab ash;
and the combination of shell plus protein, appear to produce a more
cytotoxic mixture.
A sub-lethal concentration of whole crab ash caused apoptosis in some
cells within melanoma SK-MEL-28 cell line, and at the same time, may
have induced resistance mechanisms in cells that survived treatment. In
broad terms, there were changes in expression of cytoskeletal and ER
proteins involved in protein folding, and some indications of increased
protein synthesis. A number of enzymes in the glycolytic pathway were
upregulated, suggesting a role for aerobic glycolysis, and expression of
some mitochondrial proteins was increased. Cytoskeletal changes
included increased expression of actin, myosin and tubulin; and nuclear
changes involved proteins involved in mRNA splicing.
These data are preliminary and based on semi-quantitative proteomic
analyses. Further investigation and validation of this data should be
performed using increased sample sizes, and quantitative mass
spectrometry.
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